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Abstract Thrombocytopenia is a major hematological
concern in oxidative stress-associatedpathologies and chronic
clinical disorders, where premature platelet destruction
severely affects the normal functioning of thrombosis and
hemostasis. In addition, frequent exposure of platelets to
chemical entities and therapeutic drugs immensely con-
tributes in the development of thrombocytopenia leading to
huge platelet loss, which might be fatal sometimes. Till date,
there are only few platelet protective molecules known to
combat thrombocytopenia. Hence, small molecule therapeu-
tics are extremely in need to relieve the burden on limited
treatment strategies of thrombocytopenia. In this study, we
have synthesized a series of novel 3,4,5 trisubstituted isoxa-
zole derivatives, among which compound 4a [4-methoxy-N’-
(5-methyl-3-phenylisoxazole-4-carbonyl) benzenesulfono-
hydrazide]was found to significantly ameliorate the oxidative
stress-induced platelet apoptosis by restoring various apop-
totic markers such as ROS content, cytosolic Ca2? levels,
eIF2-a phosphorylation, mitochondrial membrane depolar-
ization, cytochrome c release, caspase activation, PS exter-
nalization, and cytotoxicitymarkers. Additionally, compound
4a dose dependently inhibits collagen-induced platelet
aggregation. Hence, compound 4a can be considered as a
prospective molecule in the treatment regime of platelet
activation and apoptosis and other clinical conditions of
thrombocytopenia. Further studies might ensure the use of
compound 4a as a supplementary therapeutic agent to treat,
thrombosis and CVD-associated complications. Over all, the
study reveals a platelet protective efficacy of novel isoxazole
derivative 4a with a potential to combat oxidative stress-in-
duced platelet apoptosis.
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Introduction
Platelets are anuclear blood cells derived from bone
marrow megakaryocytes, which play an indispensable role
in hemostasis, thrombosis, and vascular integrity [1]. After
a lifespan of around 7 to 10 days, they are cleared by
reticuloendothelial system, primarily in liver and spleen
[2]. Similar to other blood cell lineages, a constant number
of mature platelets are maintained in the circulation by an
antagonistic balance between their production and
destruction [3]. Being anuclear, they are more prone to
chemical stimuli and free radicals produced during oxida-
tive stress, which trigger platelets to acquire a state of
activation. The development of many chronic health dis-
eases such as cardiovascular diseases (CVDs), cancer, and
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arthritis is associated with generation of reactive oxygen
species (ROS) that can effectively impair platelet functions
and decreased platelet count [4–8]. The reduced platelet
count in these conditions is attributed to the ROS-mediated
mitochondrial damage and subsequent platelet apoptosis
[1]. Various other conditions such as viral infection, con-
nective tissue or lymphoproliferative disorders, blood
transfusions, sepsis and acute respiratory distress syndrome
also contribute to early platelet death [9–12]. In addition to
these major contributing factors, therapeutic drug-induced
thrombocytopenia (DIT) is an emerging issue lately. Even
though therapeutic drugs are vital in treating many of the
incurable diseases, the side effects associated with these
drugs are life threatening and might be fatal [13]. Many
drugs such as methotrexate, cisplatin, vancomycin, and
aspirin are reported to cause platelet apoptosis by ROS and
various means, hence causing thrombocytopenia [14–17].
Further, few drugs are also known to stimulate a range of
hematologic alterations including reduced blood cell count
and subsequent increase in circulating microparticles
(MPs) [18], which are known to be involved in the pro-
gression of inflammation, coagulation, CVDs, cancer and
rheumatoid arthritis [19].
Therefore, in the present work, we are targeting the
often neglected ROS-induced platelet apoptosis, which is a
common feature in many of the pathophysiological con-
ditions leading to thrombocytopenia. The development of
thrombocytopenia in numerous human pathologies raises a
need for the development of new molecules, which have
the potential to alleviate stress-induced early platelet death.
However, till date, very few molecules with platelet pro-
tective efficacy are reported, which includes natural com-
pounds like crocin, cinnamtannin B1, and a synthetic
derivatives of ibuprofen and N- acetyl cysteine with pla-
telet protective efficacy [20]. Hence, search for novel
synthetic platelet protective molecules with potential to
combat against ROS-induced pathological conditions is
essential in vascular pharmacology. In this context, we
have made an attempt to synthesize novel isoxazole
derivatives, as isoxazole moiety has been recognized to
possess a wide range of biological properties such as, anti-
coagulant, antiviral, anti-apoptotic, and anti-inflammatory
properties [21–24]. Apart from these, many of the isoxa-
zole-based drugs such as sulfamethoxazole, cycloserine,
and acivicin are being commercially used for various
treatments [25]. Upon consideration of the above facts, a
series of novel isoxazole molecules (4a-h) were synthe-
sized, and for the first time, we have made an effort to
explore the platelet protective property of isoxazole
derivatives with calcium ionophore (A23187) as agonist to
induce platelet apotosis as earlier studies have reported
that A23187 enhances ROS mediated apoptosis in several
cell lines including platelets [26].
Materials and methods
Chemicals
Benzamidine hydrochloride, acetyl-Asp-Glu-Val-Asp-7-
amido-4-methylcoumarin (AC-DEVD-AMC),N-acetyl-Leu-
Glu-His-Asp trifluoromethyl coumarin (AC-LEHD-FMC),
CHAPS, dithiothreitol (DTT), dimethyl sulfoxide (DMSO),
N-(2-Hydroxyethyl) piperazine-N-ethanesulfonic acid
(HEPES), sodium orthovanadate, fluorescein isothiocyanate
(FITC)-labeled annexin, 10-nonyl acridine orange (NAO),
fura-2/AM, fluorogenic, non-fluorogenic dyes, calcium
ionophore (A23187), and MTT were from Sigma Chemicals,
USA. Monoclonal anti-cytochrome c antibody was from
Epitomics, USA. Anti-caspase-3 antibody was from Santa
CruzBiotechnology,USA.Antibodies against phospho-eIF2-
a, eIF2-a, and b-tubulin were from Cell Signalling Technol-
ogy,USA.Collagen type-Iwas fromChrono-logCorporation,
USA. LysoSensor green DND-189 was from Molecular
probes, USA. Lactate dehydrogenase (LDH) estimation kit
was purchased from Agappe Diagnostics Limited, India. 1,1-
diphenyl-2-picrylhdrazyl (DPPH) was from HiMedia Labo-
ratories, India. All the synthesized compounds (4a-h) were
solubilized in 50 % (v/v)DMSOas stock solutions and further
diluted in respective assay buffers.
The synthesis and characterization of compounds (4a-h)
are provided as supplementary information.
Antioxidant activity
The effect of isoxazole derivatives (4a-h) on DPPH radi-
cal scavenging activity was determined according to the
method of Yamaguchi et al. [27], with slight modification,
quercetin was used as reference standard. Briefly, 0.1 mM
solution of DPPH was incubated with 0–50 lM of isoxa-
zole derivatives (4a-h) for 20 min at ambient temperature
in dark, and the resulting absorbance was measured using
UV/Vis spectrophotometer at 517 nm against blank (Bio-
Mate 3S, Thermo Scientific).
Determination of ferric reducing ability
The reductive ability of the isoxazole derivatives (4a-h) was
determined according to the method of Hsieh and Yan [28].
Briefly, test compounds (0–50 lM) were incubated with
2.5 mL of sodium phosphate buffer (0.2 M, pH 6.6) con-
taining 1 % potassium ferricyanide, and the mixture was
incubated at 50 C for 20 min. At the end of incubation,
2.5 mL of 5 % TCAwas added and centrifuged at 4509g for
10 min. The upper layer (2.5 mL) was separated and mixed
with 0.5 mL of 0.1 % ferric chloride solution. Finally absor-
bance was measured at 700 nm against blank using UV/Vis
spectrophotometer (BioMate 3S, Thermo Scientific).
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Preparation of platelet-rich plasma and washed
platelets
Venous bloodwas drawn fromhealthy human volunteerswith
written consent as per the norms of Institutional Human eth-
ical committee. The study was approved and was in accor-
dance with the guidelines of the Institutional Human Ethical
Committee (IHEC-UOM No. 95/Ph.D./2013-14) University
of Mysore, Mysore. The blood drawn was instantly mixed
with acid citrate dextrose (ACD) anti-coagulant (85 mM
sodium citrate, 78 mM citric acid and 111 mM D-glucose) in
the ratio 6:1 (blood: ACD v/v) following centrifugation at
909g for 15 min to obtain platelet-rich plasma (PRP). Further
in order to get washed platelets, PRP was centrifuged at
17009g and washed twice with CGS buffer (123 mM NaCl,
33 mM D-glucose, 13 mM trisodium citrate, and pH 6.5) and
re-suspended in HEPES-buffered saline [HBS, 2.5 mM
HEPES, 150 mM NaCl, 2.5 mM KCl, 12 mM NaHCO3,
1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose, and 0.3 %
bovine serum albumin (BSA) pH 7.4].The platelet count was
determined using a Neubauer chamber and adjusted to
5 9 108 cells/mL in the final suspension using Tyrode’s
albumin buffer [145 mMNaCl, 5 mMKCl, 10 mMHEPES,
0.5 mM Na2HPO4, 1 mMMgCl2, 6 mM glucose, and 0.3 %
BSA] pH 7.4 [29].
Determination of endogenously generated ROS
The method of Lopez et al. [30] was followed to determine
the endogenous ROS production in platelets using
CMH2DCFDA, a ROS-sensitive fluorescent probe. PRP
and washed platelets were treated with A23187 (5 lM) as
agonist. For inhibition studies, pre-loaded platelets with
agonist were incubated with compound 4a in increasing
concentration (0–50 lM), and the final volume was made
up to 200 lL with HBS and incubated at 37 C for 1 h. The
control (untreated) and treated platelets were then incu-
bated with 10 lM CMH2DCFDA (excitation 488 nm and
emission at 530 nm) for 30 min at 37 C and analyzed by
Varioskan multimode plate reader (Thermo Scientifics,
USA) or flow cytometer (FACSVerseTM, BD Biosciences,
USA).
Estimation of intracellular calcium
Intracellular Ca2? level in PRP as well as washed plate-
lets was determined as described previously [31]. PRP and
washed platelet suspensions were independently treated
with A23187 (5 lM), and for inhibition studies, pre-loaded
platelets with agonist were incubated with compound 4a in
increasing concentration (0–50 lM). The final volume was
made up to 200 lL with HBS containing 1 mM CaCl2 and
incubated for 1 h at 37 C. Test samples were then
incubated with 2 lM fura-2/AM for 45 min at 37 C.
The resulting fura-2/AM fluorescence was measured by
exciting the samples at 340 and 380 nm, and the resulting
fluorescence was measured at 500 nm. Data were presented
as absorption ratios (340/380 nm).
Determination of changes in mitochondrial
membrane potential (DWm)
JC-1 dye was used to detect changes in the DWm according
to the method of Salvioli et al. [32]. Both PRP and washed
platelets were treated with A23187 (5 lM) as agonist, and
for inhibition studies, pre-loaded platelets with agonist were
incubated with compound 4a in increasing concentration
(0–50 lM) and kept for 1 h at 37 C. After incubation,
samples were then loaded with JC-1 (10 lg/mL) at 37 C
for 10 min. The cells were then excited at 488 nm and
emission was detected at 585 nm for JC-1 aggregates and
516 nm for JC-1 monomers using multimode plate reader.
Data were presented as emission ratios (585/516).
Assessment of cardiolipin peroxidation
Cardiolipin peroxidation was determined by a fluorescent
probe 10-NAO [33]. Both PRP and washed platelets were
processed as discussed above with A23187 (5 lM) as
agonist or pre-loaded platelets with agonist were incubated
with 4a in increasing concentration (0–50 lM) for inhibi-
tion studies. After incubation, samples were treated with
NAO (5 lM) for 30 min at 37 C, and the resulting fluo-
rescence was measured by exciting the samples at 499 nm,
and emission was recorded at 530 nm.
Assessment of mitochondrial permeability transition
pore (MPTP) formation
MPTP formation in platelets was assessed using calcein
AM. Washed platelets (5 9 106 cells/mL) were incubated
with agonist A23187 (5 lM) for 10 min, and for inhibition
studies, pre-loaded platelets with agonist were treated with
compound 4a in increasing concentration (0–50 lM) and
incubated at 37 C for 1 h. After incubation, calcein AM
(1 lM) was added and incubated for 30 min at 37 C. To
quench cytosolic calcein fluorescence, CoCl2 (1 mM) was
added and the resulting mitochondrial fluorescence was
measured by exciting the samples at 488 nm, and emission
was detected at 585 nm [34].
Determination of caspase activity
Caspase activity was determined with slight modification
according to the method of Amor et al. [35]. Both PRP and
washed platelets were incubated with A23187 (5 lM) and
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for inhibition studies, pre-loaded platelets with agonist
were incubated with compound 4a in increasing concen-
tration (0–50 lM) and kept at 37 C for 1 h. Platelet lysate
was prepared by adding an equal volume of 29 Triton
buffer (2 % Triton X-100, 2 mM EGTA, 100 mM Tris-
HCl—pH 7.2, 10 lg/mL leupeptin, 2 mM PMSF, 10 mM
benzamidine, and 2 mM Na3VO4) and allowed to undergo
lysis for about 30 min at 4 C. The lysate was subjected to
centrifugation at 16,0009g for 5 min. The pellet thus
obtained is the Triton-insoluble cytoskeleton-rich fraction.
Further caspase activity was measured by incubating cell
lysate in a 96-well plate with substrate solution [20 mM
HEPES, pH 7.4, 2 mM EDTA, 0.1 % CHAPS, 5 mM
DTT, and 8.25 lM caspase substrate (AC-DEVD-AMC for
caspase-3 and AC-LEHD-AFC for caspase-9)] for 2 h at
37 C. Substrate cleavage was recorded using a multimode
plate reader by excitation the samples at 360 nm and
emission at 460 nm.
Determination of phosphatidylserine (PS)
externalization
Annexin V binding of PS can be used as a reliable marker
for platelets undergoing apoptosis. Washed platelets were
incubated with A23187 (5 lM), and for inhibition studies,
pre-loaded platelets with agonist were incubated with
compound 4a in increasing concentration (0–50 lM) at
37 C for 1 h. After incubation samples were stained using
Annexin-FITC washed and analyzed by flow cytometer
[17].
Immunoblot
Washed platelets (5 9 108/mL) were stimulated by adding
A23187 (5 lM) as agonist and for inhibition studies pre-
treated platelets with agonist were treated with compound
4a (0–50 lM). After 1 h, cells were lysed with 10 lL of
HEPES buffer (10 % SDS, 20 mM N-ethylmaleimide,
20 mM sodium o-vanadate, 50 mM EDTA, and 10 mM
PMSF) and centrifuged. Following centrifugation, the
supernatants were separated on 10 % SDS-PAGE, and
proteins were transferred on to a PVDF membrane. After
blocking with 5 % non-fat milk powder in TBST, the blots
were probed with cytochrome c, caspase-3, phospho-eIF2-
a, and eIF2-a overnight at 4 C. After incubation, blots
were then treated with HRP-conjugated anti-IgG antibody
and finally developed by chemiluminescence imaging
system (Alliance 2.7, Uvitec, UK). b-tubulin was used as
loading control [36]. For re-probing, blots were incubated
in stripping buffer (200 mM glycine, pH 2.2, 1 % Tween-
20, and 0.1 % SDS) for 2 min and washed with TBST.
Blots were again treated with stripping buffer for 5 min
and washed thrice with TBST, 2 min each wash. The
stripped membrane was blocked in TBST containing 5 %
non-fat milk powder over night at 4 C and probed with
desired antibodies. Each membrane was stripped three
times maximum.
Determination of cytotoxicity by MTT and LDH
release assays
Both MTT and LDH leakage assays have been used
extensively as a marker for cell death. For MTT assay,
washed platelets in polystyrene 96-well microtiter plates
were treated with agonist A23187 (5 lM), and for inhibi-
tion studies, pre-loaded platelets with agonist were incu-
bated with compound 4a in increasing concentration
(0–50 lM), and the reaction volume was made up to
200 lL with Tyrode’s buffer. After 1 h of incubation,
250 lM of MTT was added and incubated for additional
3 h at 37 C. Finally, MTT was removed and remaining
formazan crystals were dissolved in DMSO, and the
absorbance was measured at 570 nm, using multimode
plate reader. For LDH release assay, washed platelets were
treated with agonist A23187 (5 lM), and for inhibition
studies, pre-loaded platelets with agonist were incubated
with compound 4a in increasing dose (0–50 lM) for 1 h at
37 C. After incubation, platelets were pelleted by cen-
trifugation at 17009g for 10 min, and supernatants were
used to detect LDH release by kit method, according to the
manufacturer’s protocol. The assay was performed in a
time course of decrease in NADH absorbance at 340 nm
for 3 min using spectrophotometer (BioMate 3S, Thermo
Scientific) [36].
Measurement of c -glutamyltransferase (GGT)
activity
Washed platelets (5 9 106 platelets/mL) were treated with
agonistA23187 (5 lM), and for inhibition studies, pre-treated
platelets with agonist were incubated with 4a (0–50 lM) for
1 h at 37 C. After incubation, platelets were pelleted, sus-
pended in distilled water, and lysed by sonication. The
resulting lysatewas used to determineGGTactivity according
to the previously reported method [36],which comprises of
assay mixture (1 mL) containing 4 mM c-glutamyl p-ni-
troanilide and 40 mM glycylglycine in 185 mM Tris–HCl
buffer, pH 8.2. The results were calculated using molar
extinction coefficient of p-nitroanilide (9900 M-1 cm-1) at
405 nm and expressed as mM p-nitroanilide formed/min/mg
protein.
Determination of GSH/GSSG levels
GSH and GSSG levels were determined by previously
reported [37]. In brief, pre-treated washed platelets
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(5 9 106 platelets/mL) with agonist A23187 (5 lM) were
incubated with compound 4a (0–50 lM) for 1 h at 37 C.
After incubation, platelets were incubated with o-phtha-
laldehyde (1 mg/mL) at room temperature for 15 min to
determine GSH levels, and to determine GSSG, platelets
were treated with N-ethylmaleimide (10 lM) prior to o-
phthalaldehyde addition, and the resulting fluorescence was
measured at 430 nm by exciting the samples at 365 nm.
The concentration of GSH and GSSG were determined
from the standard curve.
Determination of glucose-6-phosphate
dehydrogenase (G6PDH) activity
G6PDH activity was estimated by monitoring the increase
in absorbance at 340 nm for 3 min due to NADP?-de-
pendent glucose 6-phosphate transformation [38]. Briefly,
washed platelets (5 9 106 platelets/mL) were treated with
agonist A23187 (5 lM), and for inhibition studies, agonist
pre-treated platelets were incubated with compound 4a
(0–50 lM) for 1 h at 37 C. After incubation, platelets
were pelleted, suspended in distilled water, and lysed by
sonication. The lysates were used to determine G6PDH
activity in the reaction mixture (1 mL) containing Tris-HCl
buffer (0.05 mM, pH 7.5), 3.8 mM NADP, 3.3 mM glu-
cose-6-phosphate, and 6.3 mM MgCl2. The activity was
expressed as nmol NADPH formed/min/mg protein.
Platelet aggregation
Turbidimetric method was employed to determine platelet
aggregation using a dual channel Chrono-log model 700-2
aggregometer (Havertown, USA) as described previously
[39]. Briefly, 250 lL of PRP was taken in siliconized glass
cuvette and pre-incubated with different concentrations of
compound 4a (0–50 lM) for 3 min at 37 C and aggre-
gation was stimulated by the addition of collagen (2 lg/
mL). The resulting aggregation of platelets was followed
for 6 min with constant stirring at 1200 rpm.
Protein estimation
The method of Lowry et al. [40] was adopted for protein
estimation using BSA as standard.
Statistical analysis
Results were expressed as mean ± SEM of five independent
experiments. Statistical significance among groups were
determined by one-way analysis of variance (ANOVA)
followed by Tukey’s test for comparison of means [n = 5,
p */#\ 0.05, p **/##\ 0.01, p ***/###\ 0.001; * significant
compared to untreated platelets. # significant compared to
A23187-treated platelets].
Results
Synthesis of new isoxazole derivatives
Structurally diversified 3,5-disubstituted isoxazole-4-hy-
drazide derivatives were synthesized through the adapt-
able stepwise reactions given in Fig. 1. The reaction
between ethyl 5-methyl-3-phenylisoxazole-4-carboxylate 1
with hydrazine hydrate in ethanol under reflux condition
gave the desired scaffold 2 in good yield. The hydrazide 2
was derivatized with different sulfonyl and benzoyl chlo-
rides. Interestingly both electron donating and electron
withdrawing substituents on the phenyl sulfonyl and ben-
zoyl chlorides underwent reaction smoothly to give desired
products in good to excellent yield. The structure of all the
synthesized compounds (Table 1) was confirmed by NMR
spectroscopic and HRMS data (supplementary
information).
Fig. 1 Reaction sequence for
the synthesis of new isoxazole
derivatives: i NH2NH2.H2O,
Ethanol, 70 C, ii
phenylsulfonyl chlorides (3a-f),
pyridine, 0 C-R.T and iii
benzoyl chlorides (3g-h),
pyridine, 0 C-R.T
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Table 1 Step-wise synthesis of
3,5-disubstituted isoxazole-4-
hydrazides 4a-h Entry Sulfonyl/acyl chlorides Product
Time
(h)
Yield (%)a
1 5.0 91
2 5.0 89
3 5.0 86
4 5.5 85
5 5.5 83
6 6.0 80
7 4.0 93
8 4.0 94
a Isolated yield based on the previous step
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Free radical scavenging potentials of isoxazole
and its derivatives
Deleterious-free radical generation is the key event in
progression of many pathological conditions. During
oxidative stress, these free radicals contribute the major
role in inducing cell death. Therefore, isoxazole deriva-
tives (Table 1) were evaluated for their free radial scav-
enging potentiality prior to their determination of platelet
protective property. To begin with, reducing potential of
isoxazole derivatives (4a-4h) were assessed by ferric
reducing assay. Among the derivatives, compound 4a
showed increased radical reducing ability (Fig. 2a). Fur-
ther DPPH scavenging property of isoxazole derivatives
(4a-4h) were evaluated, where compound 4a showed
potent radical scavenging activity when compared with
other isoxazole derivatives (Fig. 2b). Based on these
results, compound 4a was considered as potent candidate
among other isoxazole derivatives and therefore appeared
to be promising for the evaluation of its anti-platelet
properties.
Compound 4a alleviates A23187-induced ROS
and intracellular calcium levels
Cellular oxidative stress plays a vital role in intrinsic mode
of platelet apoptosis, therefore compound 4a was initially
analyzed for its ROS scavenging potential in platelets.
Platelets treated with standard agonist A23187 evoked
significant ROS levels in PRP and washed platelets,
whereas compound 4a was able to reduce A23187-induced
ROS generation in a dose-dependent manner, which was
further confirmed by FACS analysis (Fig. 3a, b). Increased
levels of intracellular calcium is yet another important
oxidative stress marker, which drives platelets toward
intrinsic apoptotic pathway. Treatment of platelets with
A23187 caused an increased level of Ca2? in platelets.
However, compound 4a dose-dependently ameliorated
increased Ca2? level, and significant inhibition was
observed at 50 lM concentration (Fig. 3c). Further, 4a
dose dependently inhibited the phosphorylation of eIF2a,
which signifies the inhibition of endoplasmic reticulum
stress in platelets (Fig. 3d). Altogether, compound 4a was
found to be potent in reducing ROS content, intracellular
calcium levels, and phosphorylation of eIF2a in platelets.
Effect of compound 4a on mitochondrial membrane
potential depolarization and peroxidation
of cardiolipin
Depolarization of mitochondrial membrane potential
(DWm) and cardiolipin peroxidation are the key manifes-
tation in the intrinsic apoptotic event. DWm is a crucial
parameter for evaluation of mitochondrial function, which
was measured using JC-1 dye. Compound 4a was able to
efficiently inhibit A23187-induced DWm dissipation and
restore the DWm completely in both PRP and washed
platelets (Fig. 4a).
Further, compound 4a was assessed for its effects on
cardiolipin peroxidation using NAO. Peroxidized cardi-
olipin loses its affinity for NAO resulting in reduced flu-
orescence. Treatment of platelets with A23187 induced
significant reduction in fluorescence suggesting that there
was increased peroxidation of cardiolipin. Upon treatment
with compound 4a, there was dose-dependently restoration
of cardiolipin peroxidation in A23187-treated platelets
(Fig. 4b).
Inhibition of MPTP formation and subsequent
cytochrome c release by compound 4a
Formation of MPTP results in release of cytochrome c
from mitochondria to cytosol causing activation of cas-
pases, which are the critical regulatory events in the
intrinsic apoptotic pathway. Therefore, MPTP formation
was determined by calcein–CoCl2 quenching assay using
Fig. 2 Radical scavenging potentiality of isoxazole and its derivatives: activity measured in terms of a reducing ability toward Fe3? to Fe2? and
b DPPH radical scavenging in comparison with quercetin. Values are presented as mean ± SEM (n = 5)
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A23187 as an agonist. As anticipated, compound 4a
showed significant inhibition of MPTP formation in
A23187-treated platelets in a concentration-dependent
manner (Fig. 4c). Further, compound 4a inhibited A23187-
induced cytochrome c release from mitochondria to cytosol
as demonstrated by immunoblot (Fig. 4d).
Inhibition of caspase activity and PS externalization
by compound 4a
Caspases are critical mediators of apoptosis by their
function in hydrolyzing many of the cellular substrates.
Two specific fluorescent substrates AC-LEHD-AFC and
AC-DEVD-AMC were used in order to determine the
activities of caspase-9 and caspase-3, respectively. Treat-
ment with compound 4a, dose dependently inhibited
A23187-induced caspase-3 and caspase-9 activity (Fig. 5a,
b). Inhibition of caspase-3 was confirmed by Western blot
analysis wherein, there was significant reduction in the
cleaved form of caspase-3 in platelets treated with com-
pound 4a was observed (Fig. 4d). Further, PS externaliza-
tion, which is considered as the hallmark of apoptosis was
also evaluated in compound 4a-treated platelets. Platelets
treated with A23187 showed significant increase in PS
externalization. However, treatment with compound 4a
showed concentration-dependent inhibition of PS exter-
nalization, and significant inhibition was found at 50 lM
concentration of compound 4a (Fig. 5c).
Effect of compound 4a on G6PDH, GGT activity,
and GSH/GSSG ratio
G6PDH activity is essential in restoring NADPH levels in
cells and during oxidative stress its activity is observed to
be decreased. Further, during oxidative stress, expression
and activity of GGT is observed to be increased. Therefore,
effect of compound 4a was evaluated for G6PDH and GGT
activity in A23187-treated platelets. There was signifi-
cantly decreased G6PDH, and increased GGT activity in
platelets treated with A23187. However, compound 4a
concentration dependently restored basal levels of both
G6PDH and GGT in A23187-treated platelets (Fig. 6a, b).
Further, pre-loaded platelets with agonist showed depleted
GSH/GSSG level, while treatment with compound 4a
restored levels of GSH/GSSG as compared to untreated
platelets (Fig. 6c). The obtained results clearly demonstrate
that compound 4a inhibited A23187-induced platelet
apoptosis by mitigating oxidative stress.
Fig. 3 Effect of compound 4a on A23187-induced a endogenous
ROS generation as determined by conventional method in PRP and
washed platelets and by b FACS in washed platelets. c Intracellular
calcium level in PRP and washed platelets, and d immunoblot
showing the expression of phospho-eIF2-a in platelets treated with
A23187 in presence or absence of 4a. e Representative densitogram of
immunoblot present in panel D. Values are presented as mean ± -
SEM (n = 5), expressed as percentage increase in DCF fluorescence,
Fura-2/AM fluorescence, relative to control. *** p\ 0.001 significant
compared to control. #p\ 0.05, ##p\ 0.01, ###p\ 0.001 significant
compared to A23187
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Platelet protective effect of compound 4a
In order to determine the cytoprotective nature of com-
pound 4a, LDH leakage was measured. Treatment of pla-
telets with A23187, induced the release of LDH into
medium whereas, compound 4a was able to significantly
inhibit LDH release owing its cytoprotective property
(Fig. 7a). Further, lysosomal alkalization assay was per-
formed as healthy cells show intact lysosomes and during
apoptosis, alkalization of lysosomes occurs. Compound 4a
treatment showed concentration-dependent inhibition of
lysosomal alkalization (Fig. 7b). Similarly in order to
determine viability of platelets, MTT assay was performed.
Treatment of platelets with A23187 (5 lM) significantly
reduced the viability up to 30.58 %. However, treatment of
platelets with 4a restored the viability in a concentration-
dependent manner, and at 50 lM, 66.9 % viable platelets
were observed (Fig. 7c).
Effect of compound 4a on collagen-induced platelet
aggregation
Collagen was used as an agonist to stimulate platelet
aggregation. Pre-treatment of PRP with compound 4a at
different concentrations prior to collagen treatment resulted
in a dose-dependent inhibition of platelet aggregation. At a
concentration of 50 lM, compound 4a was able to inhibit
platelet aggregation by 99 %, (Fig. 8a, b). However,
compound 4a alone did not induce platelet aggregation.
Discussion
Thrombocytopenia is a major life threatening clinical
condition, in which a victim’s blood has an unusually low
level of platelets around 50,000/lL of blood beyond the
normal count, which is 1.5 9 105 to 4 9 105 platelets/lL
of blood. The contributing factors for the development of
thrombocytopenia are several leading to multiple formats
of health issues which is often a neglected issue in the
treatment regime [41–43]. Our continuing efforts in
developing new synthetic routes for the synthesis of vari-
ous bioactive heterocycles [44–46], prompted us to develop
a simple approach to produce structurally diversified 3,
5-disubstituted isoxazole-4-hydrazide derivatives through
adaptable step-wise reactions. Isoxazole is the basic
structure in numerous pharmaceutical drugs including
Cloxacillin and Valdecoxib which are found in wide
Fig. 4 Effect of compound 4a on A23187-induced a mitochondrial
membrane depolarization b peroxidation of cardiolipin in PRP/
washed platelets, c mitochondrial permeability transition pore
(MPTP) formation in washed platelets, and d immunoblot showing
the expression level of cytosolic cytochrome c and active caspase-3.
Representative densitograms of immunoblots of e cytosolic
cytochrome c and f active caspase-3. b-tubulin is used as loading
control. Values are presented as mean ± SEM (n = 5), expressed as
percentage decrease in JC-1 fluorescence ratio, NAO fluorescence,
and calcein fluorescence, relative to control. *** p\ 0.001 significant
compared to control. #p\ 0.05, ##p\ 0.01, ###p\ 0.001 significant
compared to A23187
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variety of natural products such as ibotenic acid. In addi-
tion, isoxazole substituted chromanes are previously
reported to protect from stress-induced neuronal damage
[47].
Based on the above observations and biological activi-
ties of isoxazole scaffolds, we have synthesized 3,4,5
trisubstitued isoxazole derivatives (4a-h) and screened for
their radical scavenging ability. Among the derivatives,
compound 4a was found to be potent antioxidant as
demonstrated by DPPH radical scavenging and ferric
reducing assays. Therefore, compound 4a was selected to
determine its platelet protective potential during oxidative
stress. In many pathological conditions, the production of
ROS is the hallmark feature in oxidative stress-induced cell
death [48]. In addition, alteration in Ca2? ion transport
mechanism brings the change in the second messenger
system leading to mitochondrial membrane depolarization,
caspase activation, PS externalization, and finally increased
platelet destruction [49]. In parallel, increased Ca2? con-
centration results in the phosphorylation of eukaryotic
initiation factor 2 alpha (eIF2-a), which is a hallmark of
ER stress [50], cell under ER stress undergoes apoptosis
mediated by caspase-12 and caspase-3. As platelets lack
caspase-12, analysis of caspase-12 was eliminated from the
study. Therefore, in the present study, A23187 (5 lM) was
used as an agonist to induce the ROS production and to
increasing intracellular Ca2? level in platelets. Compound
4a was able to alleviate ROS and restore calcium home-
ostasis with subsequent inhibition of eIF2-a phosphoryla-
tion there by reducing ER stress.
It is a well-known fact that GSH is a ubiquitous master
antioxidant in all cells, decreased reduced GSH and
increased oxidized GSH (GSSG) content seems to be an
obvious situation in increased ROS level in the platelets.
Alteration in GSH/GSSG homeostasis during oxidative
stress leads to the elevated activity of certain enzymes for
example, GGT, which is required to metabolize GSH
allowing the precursor amino acids to be reused for intra-
cellular GSH synthesis. Compound 4a which had scav-
enged ROS in platelets also showed restored GSH/GSSG
ratio and GGT activity.
Unremitting oxidative stress and increased calcium
levels also affect mitochondria by depolarizing the mem-
brane potential and peroxidizing the cardiolipin [51]. Fur-
ther peroxidized cardiolipin aids in the formation of MPTP,
through which cytochrome c is released into cytosol.
Release of cytochrome c into the cytosol serves a regula-
tory function as it precedes morphological alterations
associated with apoptosis. The released cytochrome c binds
with apoptotic protease activating factor-1 and ATP, which
Fig. 5 Effect of compound 4a on A23187 induced a caspase-9,
b caspase-3 activity in PRP/washed platelets, and c FACS analysis of
PS externalization in washed platelets. Values are presented as
mean ± SEM (n = 5), expressed as percentage increase in (a, b)
caspase activity relative to control. *** p\ 0.001 significant
compared to control. #p\ 0.05, ##p\ 0.01, ###p\ 0.001 significant
compared to A23187
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then binds to pro-caspase-9 to create a protein complex
known as apoptosome. The apoptosome cleaves the pro-
caspase-9 to its active form, which in turn activates the
effector caspase-3. Hence, cytochrome c release can be
regarded as a crucial event in the intrinsic pathway of
apoptosis [52]. Caspases are the cysteine-dependent pro-
teases that cleave proteins at aspartic acid residues and play
a crucial role in apoptosis. Generally, caspases are
expressed in an inactive pro-enzyme form as pro-caspases,
during apoptosis caspases gets activated and inturn acti-
vates other pro-caspases, allowing initiation of a protease
cascade. This proteolytic cascade amplifies the apoptotic
signaling pathway and thus ends up in PS externalization.
The expression of PS results in the early phagocytic
recognition of apoptotic cells, permitting quick
phagocytosis.
Considering these facts, compound 4a was evaluated for
its abrogation of oxidative stress-induced downstream
apoptotic markers. The compound 4a effectively inhibited
the A23187-induced membrane potential depolarization,
cardiolipin peroxidation, MPTP formation, cytochrome c
release, caspase activation, and PS externalization. Thus,
we demonstrate that compound 4a could effectively block
oxidative stress-induced mitochondrial damage and sub-
sequent caspase activation in platelets and rescued from
their premature death. Further, decreased levels of LDH
release and increased cell viabilty in A23187 treated pla-
telets confirms the cytoprotective effect of compound 4a on
platelets.
To further highlight compound 4a role as a cardio pro-
tective compound, its influence on platelet aggregation was
scrutinized. Platelets are considered to play a vital role in
the progression of atherothrombotic diseases. During vas-
cular injury, they lead up the hemostasis plug formation
and mediate thrombosis, which in turn promulgates a
multiplicity of CVDs. Platelet aggregation and adhesion
are engaged in the instigation of intraluminal thrombosis
and thus hasten heart attack, peripheral vascular occlu-
sions, and stroke [53]. Compound 4a by inhibiting colla-
gen-stimulated platelets aggregation demonstrated its
ability as an anti-platelet molecule.
Considering today’s life style which includes frequent
administration of medications, it is not surprising that DIT
is an increasingly major cause of early platelet death [13].
Along with DIT, platelets are stimulated by various agonist
including thrombin, von Willebrand factor, anti-platelet
antibodies, and intrinsic oxidative stress, which eventually
leads to the generation of platelet-derived microparticles.
The released microparticles worsen the condition by trig-
gering inflammatory cells for the production of cytokines,
Fig. 6 Effect of compound 4a on A23187 induced a glucose-6-
phosphate dehydrogenase (G6PDH) activity, b c-glutamyltransferase
(GGT) activity, and c GSH/GSSG ratio. Values are presented as
mean ± SEM (n = 5). *** p\ 0.001 significant compared to
control. #p\ 0.05, ##p\ 0.01, ###p\ 0.001 significant compared to
A23187
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elevating leukocytes adhesion to endothelial cells and
thereby altering vascular and endothelial function which
contributes in the development of CVD’s [54]. In this
scenario, there is a need and scope for novel synthetic
molecules, which can protect platelets from oxidative
stress-induced cell death. In addition, it could receive
Fig. 7 Effect of compound 4a on A23187 induced cytotoxicity in
platelets: a LDH leakage, b lysosomal stability, and c MTT cell
viability assay. Values are presented as mean ± SEM (n = 5),
expressed as percentage decrease in LSG fluorescence relative to
control. *** p\ 0.001 significant compared to control. #p\ 0.05, ##-
p\ 0.01, ###p\ 0.001 significant compared to A23187
Fig. 8 Effect of compound 4a on a platelet aggregation induced by
collagen and its inhibition by compound 4a, b graphical representa-
tion of the data showing the percentage platelet aggregation. Values
are presented as mean ± SEM (n = 5), expressed as percentage
decrease in platelet aggregation. ** p\ 0.01, *** p\ 0.001 signif-
icant compared to collagen
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greater attention by the clinicians in order to treat throm-
bocytopenia, which is a commonly occurring secondary
complication in the chemotherapy treatments. From the
current study, out of a series of novel 3,4,5 trisubstituted
isoxazole derivatives (4a-h), compound 4a was found to be
potent molecule with platelet protective efficacy by
inhibiting collagen-induced platelet aggregation and
A23187-induced apoptosis (Fig. 9).
Conclusion
In conclusion, it can be summarized that the compound 4a
is a promising molecule, which could be used in the
treatment of oxidative stress-induced thrombocytopenia
and associated pathologies. Altogether, the inhibitory
property of compound 4a on platelet apoptosis and aggre-
gation could be employed in the treatment strategy of
vascular pathophysiology and CVDs. Therefore, compound
4a could be a potential candidate in the field of vascular
pharmacology and hemostasis. Together, compound 4a has
a scope to be tested in vivo models and clinical trials for its
anti-platelet properties before its development as a new
drug to treat thrombocytopenia on the bed side.
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